Table 2.
Anti-hyperglycemic/anti-diabetic drugs alone or in combination for cancer therapy.
| Cancer | Combination | Phase | NCT No: |
|---|---|---|---|
| Metastatic colorectal cancer | Metformin, 5-Fluorouracil | Phase 2 | NCT01941953 |
| Her2 positive breast cancer | Liposomal Doxorubicin, Docetaxel, Trastuzumab, Metformin | Phase 2 | NCT02488564 |
| Breast cancer | Metformin, Doxorubicin | Phase 2 | NCT02472353 |
| Human epidermal growth factor 2 negative carcinoma of breast | Metformin, Myocet, Cyclophosphamide | Phase 2 | NCT01885013 |
| Myocet + Cyclophosphamide | |||
| Diffuse large B-cell lymphoma | Metformin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastine | Phase 2 | NCT02531308 |
| Lung cancer, Breast cancer, Pancreatic cancer, Head and neck cancer, Gastric cancer | 2-Deoxyglucose, Docetaxel | Phase 1 | NCT00096707 |
| Pancreatic cancer | Capecitabine, Cisplatin, Epirubicin, Gemcitabine, Metformin | Phase 2 | NCT01167738 |
| Prostate cancer | Rosiglitazone and Placebo | Phase 3 | NCT00182052 |
| Pancreatic cancer | Pioglitazone | Phase 2 | NCT01838317 |